Stock Scorecard
Stock Summary for Akero Therapeutics Inc (AKRO) - $51.77 as of 7/4/2025 12:30:11 AM EST
Total Score
8 out of 30
Safety Score
45 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for AKRO
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AKRO
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AKRO
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for AKRO
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for AKRO (45 out of 100)
| Stock Price Rating (Max of 10) | 9 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for AKRO
Financial Details for AKRO
Company Overview |
|
|---|---|
| Ticker | AKRO |
| Company Name | Akero Therapeutics Inc |
| Country | USA |
| Description | Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, is dedicated to developing medications designed to restore metabolic balance and improve overall health. The company is headquartered in South San Francisco, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | 8/8/2025 |
Stock Price History |
|
| Last Day Price | 51.77 |
| Price 4 Years Ago | 21.15 |
| Last Day Price Updated | 7/4/2025 12:30:11 AM EST |
| Last Day Volume | 404,821 |
| Average Daily Volume | 1,869,240 |
| 52-Week High | 58.40 |
| 52-Week Low | 21.02 |
| Last Price to 52 Week Low | 146.29% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 21.93 |
| Sector PE | 40.90 |
| 5-Year Average PE | -20.20 |
| Free Cash Flow Ratio | 22.22 |
| Industry Free Cash Flow Ratio | 17.71 |
| Sector Free Cash Flow Ratio | 32.91 |
| Current Ratio Most Recent Quarter | 16.80 |
| Total Cash Per Share | 2.33 |
| Book Value Per Share Most Recent Quarter | 13.60 |
| Price to Book Ratio | 3.78 |
| Industry Price to Book Ratio | 34.53 |
| Sector Price to Book Ratio | 30.76 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 121.97 |
| Sector Price to Sales Ratio Twelve Trailing Months | 35.60 |
| Analyst Buy Ratings | 9 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 79,718,000 |
| Market Capitalization | 4,127,000,860 |
| Institutional Ownership | 109.31% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -66.09% |
| Reported EPS 12 Trailing Months | -3.75 |
| Reported EPS Past Year | -0.90 |
| Reported EPS Prior Year | -3.75 |
| Net Income Twelve Trailing Months | -269,441,000 |
| Net Income Past Year | -252,060,000 |
| Net Income Prior Year | -151,759,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 185,922,000 |
| Total Cash Past Year | 340,238,000 |
| Total Cash Prior Year | 234,207,000 |
| Net Cash Position Most Recent Quarter | 157,111,000 |
| Net Cash Position Past Year | 304,941,000 |
| Long Term Debt Past Year | 35,297,000 |
| Long Term Debt Prior Year | 24,964,000 |
| Total Debt Most Recent Quarter | 28,811,000 |
| Equity to Debt Ratio Past Year | 0.96 |
| Equity to Debt Ratio Most Recent Quarter | 0.97 |
| Total Stockholder Equity Past Year | 750,112,000 |
| Total Stockholder Equity Prior Year | 535,306,000 |
| Total Stockholder Equity Most Recent Quarter | 1,083,846,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -262,631,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -3.29 |
| Free Cash Flow Past Year | -231,106,000 |
| Free Cash Flow Prior Year | -145,367,000 |
Options |
|
| Put/Call Ratio | 0.06 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 1.45 |
| MACD Signal | 2.22 |
| 20-Day Bollinger Lower Band | 33.01 |
| 20-Day Bollinger Middle Band | 45.89 |
| 20-Day Bollinger Upper Band | 58.78 |
| Beta | -0.16 |
| RSI | 48.86 |
| 50-Day SMA | 37.01 |
| 150-Day SMA | 34.86 |
| 200-Day SMA | 30.32 |
System |
|
| Modified | 7/3/2025 5:49:01 PM EST |